Company Overview
Alpha Teknova, Inc. operates within the healthcare sector, specifically focusing on the drug manufacturing industry for specialty and generic products, where it produces critical reagents essential for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics across the United States and internationally. The company's primary product portfolio includes specialized items such as pre-poured media plates designed for cell growth and cloning, alongside liquid microplates, which are integral to laboratory research and pharmaceutical screening processes. This entity currently maintains a market capitalization of $162.91M, generates annual revenue of $40.52M, and employs a workforce of 158 individuals to support its operations. These valuation and revenue figures indicate that Alpha Teknova functions as a mid-sized biotechnology enterprise, utilizing a lean operational structure to serve a niche market within the broader healthcare landscape while managing a relatively small employee base relative to its revenue generation.
Financial Health
The company reported a trailing twelve-month revenue of $40.52M, yet recorded a net income of -$17,259,000 and an EBITDA of -$10,134,000, revealing a significant cost structure where operating expenses and research costs substantially outpace gross profit margins. The free cash flow stands at -$2,396,250, indicating that the company is currently burning cash, which limits immediate financial flexibility for large-scale capital expenditures without external financing or asset monetization. Analysis of the three primary margins shows a gross margin of 33.2%, which is positive but insufficient to cover overhead, while the operating margin is negative at -41.2% and the profit margin is -42.6%, reflecting high operational inefficiencies or heavy investment in R&D relative to sales. Regarding liquidity and leverage, the company holds $21.34M in cash against $28.27M in debt, resulting in a debt-to-equity ratio of 41.10, which suggests a highly leveraged balance sheet where debt obligations exceed available liquid assets. However, the current ratio of 4.58 demonstrates strong short-term liquidity, implying the firm possesses ample current assets to cover its short-term liabilities despite the net debt position. Finally, the return on equity is -22.8% and the return on assets is -9.3%, metrics that reveal that management is currently eroding shareholder value and asset base efficiency, likely due to the company's stage of development and ongoing operational losses.
Valuation Assessment
Valuation metrics for Alpha Teknova present a complex picture given its profitability status, with a trailing P/E ratio of N/A and a forward P/E of -7.79, implying that the market expects earnings to remain negative or for the company to not generate positive earnings in the immediate future. The price-to-book ratio is 2.37, indicating that the market values the company at a significant premium over its net book value, which often occurs in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet. Alternative valuation multiples further highlight this divergence, with a price-to-sales ratio of 4.02 and an EV/EBITDA of -16.76, suggesting investors are pricing in future potential rather than current profitability. In terms of trading range, the stock has a 52-week high of $7.48 and a 52-week low of $1.91, meaning the current share price sits at a specific point within this volatility range relative to its recent performance history. The stock exhibits a beta of 0.40, which indicates that its price volatility is significantly lower than the broader market, suggesting it may be less sensitive to general market swings compared to larger pharmaceutical peers.
Growth & Income
Revenue growth for the trailing twelve months was 7.8%, while earnings growth is N/A due to the company's current losses, implying that top-line expansion is occurring without a corresponding improvement in bottom-line profitability. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all available earnings and cash flow back into research, development, and operational scaling rather than distributing income to shareholders. This strategy aligns with the typical lifecycle of a specialty drug manufacturer that prioritizes product pipeline advancement over immediate shareholder returns. Overall, the growth and income profile is characterized by steady revenue expansion paired with persistent negative earnings and no dividend income, reflecting a high-risk, high-reward investment thesis focused on future commercialization milestones rather than current cash generation or income yield.